SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001140361-24-013709
Filing Date
2024-03-18
Accepted
2024-03-18 07:30:39
Documents
17
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ef20024302_10ka.htm   iXBRL 10-K/A 45922
2 EXHIBIT 23.1 ef20024302_ex23-1.htm EX-23.1 2847
3 EXHIBIT 31.1 ef20024302_ex31-1.htm EX-31.1 4718
4 EXHIBIT 31.2 ef20024302_ex31-2.htm EX-31.2 4624
8 image00002.jpg GRAPHIC 3009
  Complete submission text file 0001140361-24-013709.txt   261858

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA erna-20231231.xsd EX-101.SCH 3865
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20231231_lab.xml EX-101.LAB 28240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20231231_pre.xml EX-101.PRE 20506
21 EXTRACTED XBRL INSTANCE DOCUMENT ef20024302_10ka_htm.xml XML 7153
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-11460 | Film No.: 24756925
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)